ROS1 and non-small cell lung carcinoma: Entrectinib, a CNS-penetrant tyrosine kinase inhibitor with potent activity against TRK, ROS1, and ALK fusion proteins, has demonstrated efficacy in NTRK-rearranged solid tumors such as non-small cell lung cancer and secretory carcinomas.2